Zobrazeno 1 - 10 of 34 pro vyhledávání: '"Lou Vaickus"'
3
374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors
Autor: Mary F. Mulcahy, Wael Harb, Amita Patnaik, Manmeet Ahluwalia, Suming Wang, Robert Guttendorf, Andrea Bullock, Patrick Y. Wen, Melanie Vincent, Lou Vaickus, Shubham Pant, Haider Mahdi, Jing Watnick, Manish Patel, Afshin Dowlati, Michael Cieslewicz, Marsha Crochiere, Devalingam Mahalingam, Susanna Varkey Ulahannan
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background VT1021, a cyclic pentapeptide, reprograms myeloid-derived suppressor cells (MDSCs) and induces the production of thrombospondin-1 (Tsp-1) in the tumor microenvironment (TME). Tsp-1, via binding to CD36 and CD47, induces apoptosis in tumor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0895086c40d9545d75ef962e32cd1c4f
https://doaj.org/article/cb08f1662e234a00860253c618292b87
Zobrazit plný text záznamu
4
369 Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers
Autor: Jian Chen, Manish R. Patel, Lou Vaickus, Jing Watnick, Melanie Vincent, Suming Wang, Devalingam Mahalingam, Afshin Dowlati, Randolph S. Watnick, Susanna Varkey Ulahannan, Shubham Pant, Susanne Fyfe, Michael Cieslewicz, Dejan Juric, Andrea Bullock, Mary F. Mulcahy, Marsha Crochiere
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundOne barrier to treating pancreatic cancer is the immunosuppressive tumor microenvironment (TME). VT1021 is a cyclic peptide derived from prosaposin and stimulates thrombospondin-1 (Tsp-1) production in myeloid derived suppressor cells. Tsp-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e01e023e285901889b6b1ce13ff4de16
https://doi.org/10.1136/jitc-2021-sitc2021.369
Zobrazit plný text záznamu
7
First Human Implantation of a Bioresorbable Polymer Scaffold for Acute Traumatic Spinal Cord Injury: A Clinical Pilot Study for Safety and Feasibility
Autor: Lou Vaickus, Jill Danielson, Thomas R. Ulich, Randall J. Hlubek, Nicholas Theodore, Kristin M. Neff, Alexander E. Ropper
Publikováno v: Neurosurgery. 79(2)
Background and importance A porous bioresorbable polymer scaffold has previously been tested in preclinical animal models of spinal cord contusion injury to promote appositional healing, spare white matter, decrease posttraumatic cysts, and normalize
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::062713399b381e9af9f142e4941fe67c
https://pubmed.ncbi.nlm.nih.gov/27309344
Zobrazit plný text záznamu
8
A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors
Autor: Toshio Shimizu, Mahesh Padval, Masayuki Takeda, Tutomu Iwasa, Joanna Horobin, Takeshi Yoshida, Ajit Chavan, Mitchell Keegan, Kazuhiko Nakagawa, Lou Vaickus, Kazuya Fukuoka
Publikováno v: Cancer Chemotherapy and Pharmacology
Purpose VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and proline-rich tyrosine kinase-2. This phase 1 study evaluated the safety and tolerability, pharmacokinetics, and clinical activity
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::186b7b8e03aef26abd896fcad66b8241
https://pubmed.ncbi.nlm.nih.gov/27025608
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje